Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population

Sunday, July 1, 2018
Publication cover image
George Kouris, PharmD
University of Massachusetts Medical School
Tasmina Hydery, PharmD, MBA, CGP
University of Massachusetts Medical School
Bonnie Greenwood, PharmD, BCPS
University of Massachusetts Medical School
Pavel Lavitas, PharmD, BCPS
University of Massachusetts Medical School
Mylissa Price, MPH, BS, RPh
University of Massachusetts Medical School
Karen Clements, ScD
University of Massachusetts Medical School
Caroline J. Alper, MD
University of Massachusetts Medical School
Kimberly Lenz, PharmD
University of Massachusetts Medical School
Paul L. Jeffrey, PharmD
University of Massachusetts Medical School

The Hepatitis C treatment Ledipasvir/sofosbuvir was approved by the FDA in 2015 as a once-daily regimen for the treatment of HCV. The treatment, though proven effective in controlled trials, lacked data on how well it worked in the real-world.

Researchers from UMass Medical School's Clinical Pharmacy Services and Center for Health Policy and Research tested Ledipasvir/sofosbuvir to identify predictors of treatment failure in a Massachusetts Medicaid population. They did so by carrying out a retrospective cohort study which evaluated treatment rates within a Medicaid population of 796 Primary Care Clinician and fee-for-service plan members. They found the treatment was largely successful in creating a sustained viral response, which was achieved in 95% of members.